Trial Profile
A Phase III, Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicentre Study to Assess Efficacy and Safety of Expanded Allogeneic Adipose-derived Stem Cells (eASCs) for the Treatment of Perianal Fistulising Crohn's Disease Over a Period of 24 Weeks and an Extended Follow-up Period up to 104 Weeks
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Oct 2023
Price :
$35
*
At a glance
- Drugs Darvadstrocel (Primary)
- Indications Rectal fistula
- Focus Registrational; Therapeutic Use
- Acronyms ADMIRE; ADMIRE-CD
- Sponsors Cellerix; TiGenix
- 17 Oct 2023 According to a Takeda media release, Alofisel is approved in the European Union, Israel, Switzerland, Serbia, United Kingdom and Japan based on positive data from the ADMIRE-CD study
- 27 Sep 2021 According to a Takeda media release, the company received approval from the Japan Ministry of Health, Labour and Welfare to manufacture and market Alofisel (darvadstrocel) for the treatment of complex perianal fistulas in patients with non-active or mildly active luminal Crohn's disease (CD), based on data from Darvadstrocel-3002 and ADMIRE-CD trial.
- 10 Feb 2021 According to a Takeda media release, the company has submitted an application to the Japanese Ministry of Health, Labour and Welfare to manufacture and market darvadstrocel (Cx601) for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohns disease (CD).The application filing included data from two trials, the Japanese Study Darvadstrocel-3002 and the ADMIRE-CD trial, conducted in Europe and Israel.